Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.46 |
| ▸ | CTSA | P10619 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032838 | 0.89 | POLB (0.39) | FFAR1FFAR4CTSAPTGDR2TP53 | |
| SCHEMBL2036758 | 0.87 | FFAR4 (0.42) | FFAR1FFAR4CTSAPTGDR2TP53 | |
| SCHEMBL2036530 | 0.81 | PTGDR2 (0.39) | FFAR1FFAR4CTSAPTGDR2MAPT | |
| SCHEMBL2036531 | 0.81 | PTGDR2 (0.39) | FFAR1FFAR4CTSAPTGDR2MAPT | |
| SCHEMBL2037390 | 0.80 | FYN (0.38) | CTSAPTGDR2MAPT | |
| SCHEMBL2038598 | 0.80 | DNMT3A (0.40) | FFAR1FFAR4CTSATP53MDM2 | |
| SCHEMBL2035207 | 0.78 | CTSA (0.43) | FFAR1FFAR4CTSATP53MDM2 | |
| SCHEMBL2029276 | 0.75 | FYN (0.42) | PTGDR2 | |
| SCHEMBL2029886 | 0.74 | CPT1A (0.41) | PTGDR2TP53MMEMMEL1 | |
| SCHEMBL15759922 | 0.73 | FFAR4 (0.43) | FFAR1FFAR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859611-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2512247-B1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586624-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2512247-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011075478-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | FFAR1 1030/4885FFAR4 2022/4885CTSA 3580/4885 |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | FFAR1 1030/4885FFAR4 2022/4885CTSA 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.